According to a recently published report, the In Vitro Diagnostics Market Is Expected To Grow At The Cagr Of 6.4% During 2015-2022. The segmentation of global in vitro diagnostics market is based on application, product & service, end user, technologyand geography. The report on global in vitro diagnostics market forecast, 2015-2022 (by application, product & service, end user, technology and geography) provides detailed overview and predictive analysis of the market.
Full report available global in vitro diagnostics market forecast, 2015-2022 (by application, product & service, end user, technology and geography) report at http://www.briskinsights.com/report/in-vitro-diagnostics-market
Increasing prevalence of diabetes has increased the demand for IVD. Diabetes patients regularly use IVDs in order to monitor the blood glucose. According to WHO, the number of patients suffering from diabetes were 422 million and the prevalence rate of diabetes among adults was 8.5% in 2014. Rising demand for the point of care identification and detection of several infectious diseases such as viruses & bacteria causing upper and lower respiratory tract infections including RSV, influenza, legionnaires’ disease and pneumonia along with pathogens causing filariasis and malaria is one of the key factor driving the IVD market. The other key factors that are contributing significantly towards the growth of the market are the raising awareness for personalized medicine and the growth in geriatric population. Some of the challenges faced by in vitro diagnostics market are the stringent regulatory policies and the various reimbursement issues. As per the FDA’s Federal Food Drug and Cosmetic Act, most genetic IVDs are of either Class II or Class III medical devices. In the case of Class III in vitro diagnostics, the manufacturers have to take approval from FDA before commercializing the IVD and meet some other stringent requirements.
SCOPE OF THE REPORT
1. GLOBAL IN VITRO DIAGNOSTICS MARKET BY APPLICATION 2012 – 2022 ($ BILLION)
1.1. Infectious Diseases
1.3. Autoimmune Diseases
1.8. Drug Testing
1.9. Other Applications
2. GLOBAL IN VITRO DIAGNOSTICS MARKET BY END USER 2012 – 2022 ($ BILLION)
2.2. Academic Institutes
2.3. Patient Self-Testing
2.5. Point-Of-Care Testing
3. GLOBAL IN VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICE 2012 – 2022 ($ BILLION)
3.2. Reagents & Kits
3.3. Data Management Software/Hardware
4. GLOBAL IN VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2012 – 2022 ($ BILLION)
4.3. Coagulation and Hemostasis
4.4. Clinical Chemistry
4.4.1. Electrolyte Panels
4.4.2. Lipid Profiles
4.4.3. Thyroid Function Panels
4.4.4. Basic Metabolic Panel
4.4.5. Liver Panels
4.4.6. Renal Profiles
4.4.7. Specialty Chemical Tests
4.5. Molecular Diagnostics
4.5.1. Polymerase Chain Reaction (PCR)
4.5.3. DNA Sequencing & Next-Generation Sequencing
4.5.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
4.6.1. Radioimmunoassays (RIA)
4.6.2. Western Blot
4.6.3. Rapid Tests
126.96.36.199. Fluorescence Immunoassays (FIA)
188.8.131.52. Chemiluminescence Immunoassays (CLIAs)
184.108.40.206. Colorimetric Immunoassays (CI)
5. GLOBAL IN VITRO DIAGNOSTICS MARKET REGIONAL OUTLOOK 2012-2022 ( $ BILLION)
5.1. North America
5.3. Asia Pacific
5.4. Middle East & Africa
5.5. Latin America
6. COMPANY PROFILES
6.1. Abbott Laboratories, Inc.
6.2. Alere San Diego Inc.
6.3. Becton, Dickinson and Company
6.5. Bio-Rad Laboratories, Inc.
6.6. Danaher Corporation
6.7. Elitech Group
6.8. Johnson and Johnson
6.9. Ortho Clinical Diagnostics, Inc.
6.10. Roche Diagnostics
6.11. Siemens Healthcare
6.12. Sysmex Corporation
6.13. Thermo Fisher Scientific Inc.
6.14. Transasia Bio-Medicals
6.15. Werfen Group
Release ID: 2100